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Abstract 
Introduction: Temporomandibular disorders (TMD) occur in about 10% of the adult 
general population, which makes it a considerable public health problem. Some factors 
affect treatment outcome of TMD patients seeking care, and among the factors 
influencing the prognosis of TMD pain, are comorbid pain conditions. Headaches, 
particularly migraine, have long been reported to be more frequently associated in TMD 
patients. However, evidence is lacking whether migraine is a prognostic factor for TMD 
pain at follow-up for patients undergoing TMD treatment.  
Objective: To determine in TMD pain patients who undergo common non-surgical 
treatments whether the presence of migraine at time of diagnosis is associated with worse 
TMD pain intensity at follow-up over a time period of 18 months.  
Materials and Methods: In this prospective cohort study, a consecutive sample of 99 
patients with a diagnosis of TMD pain consisting of MFP, arthralgia, and/or TMJ 
osteoarthritis according to RDC/TMD seeking care at the TMD and Orofacial Pain 
Clinic, University of Minnesota - School of Dentistry and undergoing common non-
surgical treatments for TMD were recruited. Participants received a diagnosis of migraine 
according to International Classification of Headache Disorders 2nd edition (ICHD-II, 
2004), the study exposure, at baseline. Characteristic pain intensity, the study outcome, 
was measured at 1, 6, 12 and 18 month follow-up and CPI differences at follow-up 
between patients with and without migraine were analyzed with several generalized 
equation estimation models and model selection was performed with QIC 
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(Quasilikelihood under the Independence model Criterion). Baseline CPI status and 
sociodemographic variables were added to improve the model.   
Results: At time of diagnosis (baseline), patients with migraine had a CPI level of 53.9  
(95% CI: 43.2-64.6) and patients without migraine had a CPI level of 55.8 (95% CI: 51-
60.5). At follow-up, CPI had decreased in both groups but patients with migraine had 
more pain. The statistically best fitting model predicted CPI values of 45.8, 38.4, 34.8 
and 29.2 at 1, 6, 12, and 18 months, respectively for patients without migraine. Patients 
with migraine showed model-predicted differences, additional CPI compared to patients 
without migraine, of 10.6 (95% CI: -1.6 -22.9), 8.7 (95% CI: -8.0-25.4), 5.4 (95% CI: -
7.3-18.2) and 16.5 (95% CI: 5.2-27.8) at 1, 6, 12, and 18 months, respectively. According 
to guidelines to interpret effect sizes, the effect was “small.” 
A simple, more interpretable and still statistically well fitting model predicted that CPI 
decreases 0.96 per month during follow-up and patients with migraine have 11.6  (95% 
CI: 2.7-20.4) more CPI over the time period of 1.5 years than patients without migraine. 
Conclusion: For TMD patients who undergo common non-surgical treatments, migraine 
is a potential prognostic factor for TMD pain intensity at follow-up. Patients with 
migraine at the time of diagnosis have statistically significant more TMD pain intensity 
over a time period of 1.5 years than patients without. While the migraine effect is small, 
it suggests that treatment for migraine could possibly be incorporated in the overall 
treatment plan to improve patient outcomes.  
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1. Introduction  
Temporomandibular disorders (TMD) is typically a painful condition of the 
masticatory muscles, the temporomandibular joints, or both. The prevalence of this group 
of conditions is about 10% in the adult general population, which makes it a considerable 
public health problem and affects substantially individuals’ quality of life (1-3) and it 
impacts substantially individuals’ quality of life (4, 5). Some individuals have chronic 
pain and while treatment outcome is favorable when care is sought, some patients receive 
insufficient relief from conservative or even invasive therapeutic approaches. Among the 
factors influencing the prognosis of TMD pain, comorbid pain conditions are considered 
very important. Conditions such as widespread pain and fibromyalgia are often associated 
with TMD pain and they impact the treatment outcome (6, 7).  
Other pains in close proximity to TMD pain are naturally potent candidates to 
influence TMD prognosis. Headaches, particularly migraine, have long been reported to 
be more frequently associated in TMD patients (8). One study reported that headaches 
occurred significantly more in subjects with symptoms of TMD pain rather than in those 
without TMD pain (27.4% versus 15.2%). Another study observed that the overall 
prevalence of headache in TMD pain patients was 72.7% higher than a control group 
(without TMD pain) with 31.9% (9). A particular type of headache, migraine, may be 
particularly important because worldwide, it is the third most common disease and has an 
estimated prevalence of 14.7% (10). The relevance of migraine for TMD pain could be 
due to shared mechanisms, and although the origin and mechanisms for these conditions 
have not been completely established, there is consensus that the trigeminal nerve is 
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associated with both conditions. Once pain is established, referral anywhere in the 
trigeminal and cervical complex can occur through central sensitization, and can be 
amplified by peripheral inputs (11-14).  
Studies investigating the relationship between TMD and migraine have looked at 
the similarities between signs and symptoms of both disorders (15-17). Some studies 
have established that both migraine and TMD are more prevalent in younger adults and 
decline in frequency with age and in women during postmenopausal years (2). Hormonal 
factors also play a role in TMD with pain levels varying across the menstrual cycle (18). 
There are also studies that found that women with migraines are more likely to have 
TMD pain when compared to women without migraines (19). Nevertheless, they have not 
investigated whether the presence of migraine is a predictive factor for the prognosis of 
TMD pain for patients undergoing common conservative treatment.  
To study whether migraine is a prognostic factor for TMD pain at follow-up for 
patients undergoing TMD treatment has relevance. Beyond advancing our knowledge 
about mechanisms of pain conditions, treatment of migraines could potentially improve 
TMD pain follow-up, i.e., it could decrease the suffering for a substantial number of 
TMD patients because migraine is not rare. An observational study in typical TMD 
patients with a widely applicable diagnosis using RDC/TMD and a standardized migraine 
assessment could be the first step for establishing the migraine-TMD pain at follow-up 
relationship that could be followed by other more confirmatory studies that also 
determine the magnitude of a treatment effect when patients suffer from TMD pain and 
migraine.  
    
 3 
2. Aim and Hypothesis  
 
Aim 
We aimed to determine in TMD pain patients who undergo common non-surgical 
treatments whether the presence of migraine at time of diagnosis is associated with worse 
TMD pain intensity at follow-up over a time period of 18 months.  
                         
Hypothesis 
Our research hypothesis was that TMD pain patients with migraine have higher, 
i.e., worse TMD pain intensity over the course of 18 months compared to patients 
without migraine.  
The statistical null hypothesis is that, when taking into account patient’s baseline 
measures, there is no difference in pain intensity over a time period of 18 months 
between TMD pain patients with and without migraine that are undergoing non-surgical 
TMD treatments.  
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3. Material and Methods 
 
3.1. Subjects and setting 
In this prospective cohort study, a consecutive sample of patients seeking care at 
the TMD and Orofacial Pain Clinic, University of Minnesota - School of Dentistry were 
enrolled in 2010 and 2011. Participants were included when masticatory muscle and 
TMJ-related pain was their primary concern, if they were at least 18 years of age, and if 
they fulfilled the criteria for TMD pain diagnosis according to Research Diagnostic 
Criteria for Temporomandibular Disorders Version 2 (20). Patients were excluded when 
they were planning to move town or would be out of the country during the follow-ups, if 
they required an interpreter in the initial consultation or had an insufficient command of 
the English language, and if they had mental impairments that prevented accurate 
answers to questions.  
At the time of diagnosis (baseline), TMD pain patients were asked to fill out a 
questionnaire that comprehended questions needed for the diagnosis of TMD pain. It also 
included questions about the baseline status of the study’s outcome characteristic pain 
intensity (CPI) and other pain-related questions. Filling in the questionnaire took about 
10 min of the patient’s time. 
The study protocol (IRB number 0911M74077) was reviewed and approved by 
the Institutional Review Board of the School of Dentistry, University of Minnesota. After 
patients signed the informed consent, the 99 patients started regular standard non-surgical 
treatments for TMD pain.  
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Study exposure: Presence of migraine 
Subjects were classified according to their diagnosis of migraine, based on the 
International Classification of Headache Disorders 2nd edition (21). The attending 
resident and faculty established the migraine diagnoses after detailed evaluation of 
patient’s history and comprehensive clinical exam of each participant. Regarding the 
migraine diagnosis, the frequency of attacks was not taken into consideration; therefore, 
episodic migraine and chronic migraine were considered as migraine only.  
 
3.2.  Study outcome: Assessment of pain intensity 
Characteristic pain intensity is an average of three aspects of pain intensity: pain 
at the moment, worst pain and average pain in the past 6 months. Responses are given on 
a 0 to 10 scale, with 0 being no pain and 10 being as bad as it could be. CPI score ranges 
from 0 to 100 points (higher scores indicate greater pain). The three pain intensities were 
recorded with the Graded Chronic Pain Status (22) which is a 7-item instrument that is 
frequently used to measure chronic pain severity in epidemiological studies. It is 
multidimensional measure that assesses 2 dimensions of overall chronic pain severity: 
pain intensity and pain-related disability.  
  The CPI was recorded at 1, 6, 12 and 18 months after initial diagnosis. Patients 
were mailed a questionnaire with the Graded Chronic Pain instrument, and other pain-
related questions that required about 5 min of the patient’s time to fill in the information.  
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3.3 Data analyses  
CPI differences for patients with and without migraine were calculated for all 
follow-ups individually. Confidence intervals for the differences were also computed and 
their statistical significance was evaluated. 
 
Then, all CPI scores at 1, 6, 12, and 18 months were analyzed together in 
generalized estimating equation (GEE) models. The GEE method is an extension of the 
generalized linear model (GLM) method to correlated data and to obtain valid standard 
error of the parameter estimates. One key difference compared to regular regression 
analysis is that GEE method is based on the quasilikelihood theory and no assumption is 
made about the distribution of response observations. 
Our data modeling approach progresses in four steps: 
1. We included baseline CPI in the model to provide a desired interpretation for 
the analysis that CPI differences at follow-up between patients with and 
without migraines are independent of initial CPI status. 
2. We built eight models that we deemed potential competitors for explaining the 
data and selected the best model. 
3. We added more covariates to adjust for potential confounders and adjust for 
treatment modality influence. 
4. Finally, the robustness of the findings was checked with data imputation and 
model diagnostics.  
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Model building step 1: 
We included baseline CPI as a covariate in the model. This variable was 
incorporated so that follow-up CPI differences (our outcome) between migraineurs and 
non-migraineurs for the same initial CPI level can be computed. Without this variable in 
the model, follow-up CPI differences could just be a continuation of baseline differences 
between patients with and without migraine. Differences at follow-up could have been 
observed, but these differences could already be present at baseline. With baseline CPI in 
the model, CPI differences at follow-up were computed for patients with the same level 
of initial CPI and, therefore, the influence of baseline CPI is adjusted for.  
 
Model building step 2: 
In our strategy to analyze the CPI differences at follow-up between patients with 
and without migraine, i.e., the exposure variable of interest, we incorporated in the 
analyses the time when the follow-up was performed. We did this in several ways: 
1. We added follow-up time as a categorical main effect to the analysis and also 
created an interaction effect with the other, already present main effect, our 
exposure variable migraine presence (Panel A, Figure 1). This model allowed 
the CPI follow-up differences between patients with and without migraine to 
vary freely over follow-up time. In this model, the four CPI differences at 
follow-up can have all different values. 
2. We added follow-up time as a linear main effect and also created an 
interaction effect with the migraine main effect (Panel B, Figure 1). This 
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model was more restrictive than model 1. It allowed the CPI follow-up 
differences between patients with and without migraine to vary, but they 
varied systematically with follow-up time. Two scenarios could potentially 
exist. The CPI differences between patients with and without migraine 
became increasingly larger (as depicted in Panel B, Figure 1) or they could 
become increasingly smaller. For both scenarios, the four CPI differences at 
follow-up could have all different values, but the difference was function of 
time, i.e., they increased (e.g., Panel B, Figure 1) or decreased with a constant 
factor over follow-up time. 
3. We added follow-up time as a categorical main effect to the analysis, but did 
not add an interaction with the study exposure (Panel C, Figure 1). This model 
was a simpler version of model 1. The CPI differences between patients with 
and without migraine could not vary freely in their magnitude over follow-up 
time anymore. The difference was now constant and consequently instead of 
four CPI differences at follow-up, only one difference was derived in the 
analysis. However, the constant CPI difference was added to freely varying 
CPI levels of the no migraine group (the base group in the analysis). 
4. We added follow-up time as a linear main effect, but did not add an 
interaction with the study exposure (Panel D, Figure 1). This model was a 
simpler version of model 2. However, it also shared some similarities with 
model 3 because, like this model, it only contained main effects. This was the 
simplest model of the four. The CPI differences were constant over time. Only 
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one difference is derived in the analysis. In both patients with and without 
migraine, CPI decreased as a function of follow-up time.   
 
We already noted that follow-up CPI scores were correlated and the GEE model 
took this into account in the analysis. However, the pattern of the correlation or the 
correlation structure was informative and also needed to be incorporated in the analyses. 
The GEE model can take this correlation structure into account. Two options for 
modeling this correlation were explored: an unstructured correlation structure and the 
more restrictive, but parsimonious, exchangeable working correlation matrix. Whereas 
the unstructured correlation did not make any assumption about the magnitude of the 
correlation, the exchangeable correlation matrix assumed that all follow-up measures for 
an individual are equally correlated. For example, if the matrix would contain a 
correlation of 0.5, then CPI scores at 1 month correlated with rho=0.50 with the CPI 
scores at 6 months. Also, the 6 month scores correlated with rho=0.50 with the 12-month 
scores etc.  
Our four models could all be used with the unstructured or the exchangeable 
correlation structure. Therefore, eight possible models were investigated as possible 
candidates to explain the data. The selection of the best among the eight available models 
was performed using QIC (Quasilikelihood under the Independence model Criterion), a 
method of evaluating model fit for the GEE approach (23). The QIC method allows us to 
compare models with different parameterizations (different variables in the models, e.g., 
model 1 through 4) as well as alternative correlation structures (for example, unstructured 
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or exchangeable correlations) on the same data. In short, a model with the lowest QIC 
was considered the “best” model in terms of statistical fit.  
 
Model building step 3: 
We also added gender, age, education and treatment modality to the analyses. The 
sociodemographic variables would be considered confounders of the migraine-TMD with 
CPI relationship. Education was grouped as some high school education and at least 
some college education. Ethnicity was defined as White (Not Hispanic or Latino) and 
Non-white (Hispanic or Latino). Treatment variables were added to compare CPI for 
migraineurs and non-migraineurs with similar clinical treatment and therefore to adjust 
for a possible treatment influence. We divided patients into three categories: treatment A 
(Patient education/TMD self-care only - SC), treatment B (SC with one additional 
treatment, either physical therapy or splint) and treatment C (SC with both physical 
therapy and splint).  Physical therapy incorporated any of the following: therapeutic and 
home exercises, manual therapy and/or modalities. Splint was defined as a stabilization 
appliance with a flat plane design or a mandibular repositioning appliance.  
 
Model building step 4: 
Finally, we were concerned about the influence of missing CPI follow-up 
information. The number of participants that completed follow-ups was 54.4% at 1-
month follow-up, 35.6% for 6 and 12 months, and 55.4% for 1.5 years follow-up. 
Missing data were imputed. We performed multiple imputations. We generated 10 data 
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sets and generated the final statistical model in each of the 10, now complete data sets. 
Then, the GEE model results for each complete set were averaged across the 10 datasets. 
Before we performed the imputation, we analyzed whether baseline sociodemographic 
and clinical characteristics influence missing data. When performing the imputation, we 
took follow-up time, exposures status, and baseline CPI level as influencing factors for 
imputation of the missing data into account. We intended to counteract any influence 
from these factors on the missing data. If these variables would have an influence 
whether data were missing or not, e.g., data was systematically missing according to the 
patient’s initial CPI level, we would expect to see differences between the data analyses 
with and without imputation. As the last step, we performed model diagnostics to check 
the robustness of our analytic approach. We calculated “dfbetas”, a measure of how much 
an observation has effected the regression model estimation (there is one DFBETA for 
each observation in the dataset). Values larger than 2/sqrt(n) in absolute value were 
considered highly influential. For interpretation of the magnitude of the migraine and 
other factors’ effects in the model, we calculated “omega-squared” for models with 
unstructured correlation matrix and compared effect size values with guidelines (24). 
All analyses were performed using the statistical software package STATA/IC, 
Release 14 (StataCorp LP, College Station, TX, USA), with probability of a type I error 
set at 0.05.   
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4. Results 
4.1. Sociodemographic and clinical characteristics as well as baseline CPI of 
TMD pain patients with and without migraine.  
In this consecutive group of TMD pain patients, about every fifth individual 
suffered from migraine (Table 1). However, patients with and without migraine did not 
differ much by age and ethnicity and only slightly differed by gender, education and 
treatment modalities. Most importantly, regardless of the presence of migraine, patients 
were comparable in their baseline TMD-CPI, i.e., they suffered from similar, moderately 
intense pain before treatment started. Both groups of patients only differed a trivial two 
points on the 0 to 100 CPI scale. Overall, patients with and without migraine seemed to 
be similar at baseline and also received similar treatments. 
In addition, all participants were stratified by number of follow-ups to evaluate if 
there was a significant difference due to missingness of one or more follow-ups (Table 
2). Patients with and without migraine at baseline did not differ to a substantial degree in 
their characteristics and none of the differences was statistically significant. The baseline 
CPI levels were comparable between these two groups, with a slightly difference of 3 
points. Findings suggest that it is unlikely that patients with migraine and with high 
follow-up CPI levels are missing. Therefore, the CPI differences at follow-up would not 
be affected by missing data. The difference is also not statistically significant if the 
presence of migraine is taken into account.  
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4.2. CPI differences between patients with and without migraine: individual 
analysis at each follow-up 
CPI declined over time in patients with and without migraine. At the end of the 
study observation time, only about half of the initial pain intensity was still present. Pain 
after 1.5 years was on average mild in intensity. At two of the four follow-ups, patients 
without migraine had lower CPI. On two occasions no difference was observed. 
Confidence intervals for the differences were wide, indicating a substantial uncertainty 
and always included a zero difference, i.e., they were statistically not significant.  
 
4.3. CPI differences between patients with and without migraine: Combined 
analysis for all follow-ups and model building 
In the GEE analysis, when the CPIs of the four follow-ups were analyzed together 
and baseline CPI was included to compare patients with and without migraine with 
similar initial pain intensity (model building step 1), the situation changed. Overall, 
patients with and without migraine differed more in their CPI at follow-up. Patients with 
migraine had higher CPI, i.e., they did not decline in their pain intensity as much as 
patients without migraine.  
When we compared the eight statistical models according to the QIC (model 
building step 2, Table 3), the best model of follow-up CPI measures was model 1 with 
month as categorical variable and an interaction of this variable with migraine, estimated 
using an exchangeable correlation structure. This model generated four CPI differences, 
one for each follow-up. The difference represented the added CPI at follow-up for 
patients who have migraines at time of diagnosis compared to the CPI for patients 
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without migraines. The model-derived CPI differences are presented in Figure 2. 
Confidence intervals for the differences are presented in Table 4. 
 
In our further model building steps, results did not change much. Adding covariates 
changed the CPI difference only slightly by 3 points or less (Table 4). Finally, model 
results were deemed to be robust because imputation did not provide substantially 
different results. The best fit model was evaluated for outliers and influential 
observations by calculating the dfbeta statistic for each observation. The dfbetas ranged 
from -0.8 to 2.0. There were 2 observations where dfbeta was greater than 1.0 and 43 
observations where dfbeta was greater than 0.1 (using the criteria of 2/squareroot(n) as a 
criteria for influence.) The model was rerun after deleting these potential outliers and 
estimates for the effect of migraine before and after deletion of these observations were 
not substantially different.  
 
4.4.  Alternative model to provide a better interpretation of the findings 
For simplicity and ease of interpretation, it may be beneficial to consider a 
simpler model with only migraine exposure and time as a linear variable in its original 
metric months with no interactions of the two variables.   
The model fit for this model was comparable to the model fit of the “best” model 
(QIC= 56085.82 vs. QIC=55343.11) and the interpretation of the model may be more 
easily understood and estimated. The model assumed that follow-up CPI level was a 
function of time, i.e., TMD pain intensity decreased per month by a certain number of 
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CPI points. In our situation, CPI decreased by 0.96 (95% confidence interval: 0.66 to 
1.25) per month. This model-generated decrease was identical in patients with and 
without migraines; however, these two groups differed by 11.6 (95% confidence interval: 
2.7 to 20.4) – a difference that was constant over the time of 18 months. For example, at 
month 1 patients with migraine had a CPI of 56.7 whereas patients without migraine had 
a value of 45.1. Because of our model structure, the difference of 11.6 between the two 
values was still the same at month 18, but now the CPI levels were 40.5 and 28.9 for both 
groups, respectively. Therefore, patients with migraine improved in their pain intensity 
by the same rate over time, but their TMD pain magnitude was always worse at a certain 
follow-up compared to patients without migraine.  This model assumed a constant effect 
of migraine across all time points and, as before for the more complicated, best fitting 
model, identical correlations between outcome (CPI) measures within an individuals’ 
repeated observations.  
Effect sizes (omega-squared) were calculated for the alternative plus covariates 
model. The migraine and time effects were small (omega-squared 0.03 and 0.12, 
respectively). The effect size was large for baseline CPI (0.30).  
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5. Discussion 
 
In this prospective cohort study, we found that patients perceived a steady decline 
in their pain intensity over the time of 1.5 years and, at the end of this time period, pain 
dropped to 28.9 CPI points on the non-migraineur group. In comparison, patients with 
migraine had additional 11.6 CPI points at this point. Therefore, in TMD patients we 
found an association between baseline migraine, and TMD pain intensity at follow-up. 
The effect was small, but statistically significant.   
Several peer-reviewed articles have reported different thresholds for what should 
be considered clinically meaningful pain difference (25-30). The rational for those 
attempts are to judge the relevance of the pain experience, and its difference between 
groups of conditions. The existence of different thresholds, for what should be considered 
clinically meaningful pain difference, point to two relevant aspects: First, there is a lively 
debate in various areas of the study of pain, and, second, that the “clinical difference” is 
not yet completely established. In essence, there is a large variability in the reported pain 
ratings across individuals, despite seemingly similar stimuli or interventions (29). 
Moreover, researchers, clinicians and patients, depending on which criteria was chosen, 
very often interpret values obtained from pain measurement scales differently (27).  
On an attempt to provide some guidelines for this interpretation, the Initiative on 
Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) 
recommends that the percentage of patients obtaining reductions in pain intensity from 
baseline of at least 30% should be reported (28, 31). This was the guideline used in this 
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study, and this is relevant because patients considered a 30% reduction in pain intensity 
as moderate improvement in previous peer-reviewed studies (28, 30, 32). In our study, 
patients did not perceive a constant percent pain difference over the study period. After 
1.5 years, patients with migraine experienced 40% more pain at the end of the study 
compared to patients without migraine. This is a difference we believe would matter to 
these patients. The same guideline also recommends researchers to report cases of pain 
reductions greater then a 2-point difference in pain reduction. A 2-point pain reduction 
would be equivalent to 20 points on the CPI scale. While pain intensity in both migraine 
and non-migraine groups reduced over 1.5 years, for patients without migraine it was 
substantially larger. In the non-migraine group, the drop was 26.9 CPI points and in the 
migraine group the decrease was 13.4 points. According to the guideline, in the non-
migraine group the pain reduction is relevant according to the 2-point criterion.  In the 
migraine group it is not. In relative terms, pain intensity dropped 48% in the non-
migraine group and 25% in the migraine group. According to the guideline, in the non-
migraine group the pain reduction is relevant according to the 30% criterion. In the 
migraine group it is not. It should also be noted that the difference between the two 
groups of 11.6, i.e., equivalent to 1.16 on a 0-10 numerical rating scale, did not reach the 
2-point criterion and would not be considered clinical relevant.  
Summarizing these points, a clinical significant effect was observed according to 
most criteria of clinical relevance but not for all, leaving some uncertainly about the 
magnitude of the effect.   
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The discussion of clinical relevance also benefits from another perspective. An 
important aspect that should be considered is that the baseline CPI levels for the 
participants in this study ranged from 53.9 to 55.8. According to a consensus statement 
from IMMPACT (28), the magnitude of pain reduction that a participant with severe pain 
would consider minimally important could be greater than the magnitude of reduction 
that an individual with mild or moderate pain would consider. Therefore, not all patients 
have experienced a meaningful change. Also, although the use of percentage change can 
have the potential to correct patients’ assessments of differences, the role of baseline pain 
should be evaluated in each specific situation. Thus, we cautiously followed these 
recommendations. 
In our study, after rigorous and meaningful statistical consideration and analyses, 
we observed a statistical difference over the 18-month follow-up time. Considering the 
evidence reported on table 4, the best model (model 2) and the best model plus covariates 
(model 3) show that the migraineur group had 15 (model 2) and 16.5 (model 3) more CPI 
points then the non-migraineur group, when taking baseline levels into consideration. If 
we consider a more robust and parsimonious model (alternative model plus covariates) 
the migraineur group demonstrated additional 11.6 CPI points. This is a conservative 
perspective for interpretation of treatment effects.  
More insight comes from other studies. A randomized controlled trial by Truelove 
et al (33) found findings with similar magnitude in terms of CPI reduction levels at a 
shorter follow-up period (12 months) and with the participants having moderate baseline 
CPI levels similar to our population group. Therefore, baseline levels of pain intensity are 
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indeed very influential like in our study, providing supporting information about pain 
reduction in other TMD patient populations.  
 
While our statistical modeling revealed a complex pattern of varying pain 
intensity at the different follow-ups in terms of the values for the base group of non-
migraineurs as well as the difference of migraineurs compared to the previous group, we 
were also able to detect a well-fitting parsimonious and clinically very plausible model. 
In this model, pain decreased in a linear fashion from baseline intensity and we can 
characterize the migraine effect as constant worsening of pain intensity over the entire 
time. In addition, the follow-up CPI scores were correlated to the same degree in our 
study where the time distances between follow-ups were pretty similar. The 
characteristics of a linear pain decrease, a constant migraine effect and identical 
correlations between outcomes are certainly a simplification of a complex process; 
however, in our situation they provided a reasonable and simple explanation, i.e., model, 
of the data. We also believe that this model sheds some light into how treatments and 
prognostic factor affect patient outcomes in general.  
 
Comparison with previous findings 
Our findings are in line with studies showing an influence of comorbid pain 
conditions on prognosis of patients with TMD pain. Comorbid pain is frequent in TMD 
pain patients. Studies that evaluated the effect of different comorbidities in TMD pain 
showed that 60% of subjects with TMD pain reported concurrent bodily pain conditions 
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in addition to pain in the facial region (34). Treatment outcomes at follow-ups are further 
impacted by the presence of concomitant diagnoses (6, 7, 35). More specifically in the 
field of orofacial pain, observational studies evaluating the effect of migraine on TMD 
pain showed a migraine diagnosis being not only associated with TMD, but also 
positively associated with increased TMD pain intensity (9, 36-38). However, these 
studies generally used either questionnaire for classification of migraine and TMD pain, 
and/or cross-section study design. We mitigated these limitations by performing a 
comprehensive clinical and physical exam, which is considered the gold standard for 
classification. We also performed a prospective, longitudinal study, allowing the 
determination of a cause-and-effect-relationship. Since the origin of migraine and TMD 
pain has not yet been established, possible mechanisms for a poor prognosis and 
treatment outcome can only be speculated. However, the phenomenon of central 
sensitization in the trigeminal distribution may offer an explanation. The combination of 
inputs from neurons in the nucleus caudalis (integrates nociceptive input from both 
intracranial and extracranial tissues) is projected to the thalamus and onto the cortex (39). 
Thus, nociceptive inputs from the TMJ and/or masticatory muscles could lead to 
trigeminal activation (14). In addition, the presence of proinflammatory factors 
(prostaglandin E2, cytokines and tumor necrosis factor), Calcitonin gene-related peptide, 
nociceptive substance P and serotonin at the TMJ could be another form of sensitization 
(40-42). Therefore, TMD symptoms could cause an excitatory impact on migraine. 
Equally, it is possible that migraine leads to activation of the trigeminal system increasing 
the susceptibility for TMD pain, also via similar mechanism of central sensitization (12, 
    
 21 
14). In summary, TMD pain may be a source of headache and perhaps worsen preexisting 
headache. The opposite may also be true.    
In the literature, there are very few studies designed to clinically evaluate 
association between headache and TMD pain over time periods that are clinically 
relevant (43, 44). One of the previous studies concluded that in female patients with 
comorbid migraine and TMD pain, treating migraine alone was no different than not 
treating migraine, and treating only TMD pain was also not effective. The better patient 
response and treatment outcome was observed when combining treatment to address both 
disorders simultaneously (45).  
 
Strengths and limitations 
The present study has several strengths. Our study design comprehended a 
meaningful 18-month follow-up period, which is clinically informative. Patients were 
diagnosed following the gold-standard approach with complete clinical exam following 
valid international guidelines (20, 21, 46, 47). Although we selected participants from a 
specialized center at a major university, the sample could be similar to broader population 
studies, since many patients in our sample had their first treatment while participating in 
this study. The majority of our sample was female, young adults and educated; which is 
consistent with the demographics of both migraine and TMD pain studies (2, 19, 48). 
Their baseline pain severity is also similar to other patient population, and while patient 
populations may differ, the influence on our findings comparing between TMD pain with 
and without migraine is likely less pronounced. Our primary outcome was pain intensity 
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(measured by CPI from the GCP) that is a recommended core outcome measure by 
IMMPACT (31). In addition, our statistical analysis was comprehensive and based on 
specific methods for longitudinal studies by using the GEE approach. Results with and 
without covariate adjustment were similar, indicating that sociodemographic factors and 
treatment modalities did not have a substantial influence on the findings. 
Our study also has some limitations. Although there are different and 
contradictory recommendations in the pain literature on what should be considered a 
positive clinical change, we based the interpretation of our findings on an international 
valid guideline (28, 31, 49). Nevertheless, we recognize that there are other debatable 
methods to report minimal clinically important difference (MCID), such as anchor-based 
and distribution-based MICD approaches (50, 51). We also only used pain intensity as 
the outcome measurement. Several other multidimensional physical and psychosocial 
measures could be used in addition to pain severity. However, pain intensity is one of the 
four core domains for chronic pain outcomes (28). We could have assessed migraine 
presence at each follow-up. This would have led to a different research question than our 
interest in the prognostic value of migraine presence when the patients is diagnosed and 
starts treatment.  In regards to treatment, we do know which treatments were 
recommended to the participants; however, we did not evaluate if and when patients 
stopped their treatments. Most likely, they continued with some TMD self-care. Finally, 
we had a low response rate resulting in substantial missing data. While we cannot 
exclude a bias due to non-response, our data imputation adjusted for major 
methodological threats such as missingness influenced by baseline TMD pain intensity. 
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Additional non-response analyses did not find evidence for a major bias due to non-
response. Our findings seemed robust also against outliers in the data.  
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6. Conclusion  
 
In summary, the results presented support for the conclusion that migraine could 
be considered a potential prognostic factor for worse pain intensity at follow-up in TMD 
pain patients being treated by common non-surgical treatments for TMD. The magnitude 
and the clinical relevance of this effect are challenging to interpret due to different 
guidelines available for the absolute and the relative size of the change.  
Future longitudinal clinical studies are needed to evaluate if and how much pain 
severity and disability would improve treating both conditions concurrently. However, 
given the cumulative evidence suggesting the comorbid nature of TMD pain and 
migraine and the two conditions bidirectional relationship, our findings point into the 
direction that combined therapeutically approach, addressing both conditions 
simultaneously, in patients with TMD and migraine could possibly lead to improved 
outcomes in these patients.   
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Table 1: Sociodemographical and clinical characteristics of TMD pain patients with and 
without migraine as comorbid condition. 
 
  
TMD patients  
without migraine 
  
TMD patients 
with migraine  
  
 
 N 
mean (SD)  
or %  N 
mean (SD)  
or %  
Difference  
between means  
(95% CI) 
p-valuea 
Age [years] 81 37.5 (13.3) 
 
18 35.2 (14.0) 
  
0.51 
Female 81 72% 
 
18 89% 
  
0.14 
≥Some college 81 77% 
 
18 89% 
  
0.26 
White  81 96% 
 
18 94% 
  
0.72 
Treatment A 81 12% 
 
18 6% 
  
0.42 
Treatment B 81 56% 
 
18 50% 
  
0.67 
Treatment C  81 32% 
 
18 44% 
  
0.32 
        
 
CPI baseline 81 55.8 (21.4) 
 
18 53.9 (21.5) 
 
1.9 
(-9.2 to 12.9) 
 
CPI 1 month FU 46 45.4 (18.2) 
 
9 50.7 (24.0) 
 
-5.3 
(-19.3 to 8.7) 
 
CPI 6 months FU 32 35.9 (21.6) 
 
4 35.8 (28.9) 
 
0.1 
(-23.9 to 24.1) 
 
CPI 12 months FU 27 34.1 (20.7) 
 
9 33.3 (28.8) 
 
0.7 
(-17.2 to 18.7) 
 
CPI 18 months FU 45 26.5 (21.1) 
 
11 35.8 (26.4) 
 
-9.2  
(-24.2 to 5.7) 
 
a) p-value derived from logistic regression. 
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Table 2: Sociodemographical and clinical characteristics of all patients and stratified by 
number of follow-ups.  
 
Characteristic 
 
All patients 
 
  
Patients who 
completed all 
follow-ups  
 
 
Patients who 
missed at least 
one follow-up 
 
 
 
N 
mean (SD) or 
proportion of 
subjects 
 
N 
mean (SD) or 
proportion of 
subjects N 
mean (SD) or 
proportion of 
subjects 
p-valuea 
Age [years] 99 37.0 (13.4) 
 
19 35.8 (15.1) 80 37.3 (13.0) 0.65 
Female 99 75 % 
 
19 74% 80 75% 0.90 
≥Some college 99 78 % 
 
19 84% 80 77% 0.75 
White  99 96 % 
 
19 95% 80 96% 0.58 
Treatment A 99 80 % 
 
19 79% 80 81% 0.75 
Treatment B 99 42 % 
 
19 37% 80 44% 0.58 
Migraine 99 18 % 
 
19 16% 80 19% 1.00 
CPI baseline 
[points] 99 55.4 (21.3) 
 
19 52.8 (20.6) 80 56.0 (21.5) 
 
0.55 
a) Statistical significance comparing patients with complete and incomplete follow-ups  
    
 27 
Table 3: Comparison of eight candidate models to characterize CPI in TMD patients 
undergoing treatment over a time period of 1.5 years: QIC for model selection under 
normal distribution. 
 
Correlation 
Structure  Variables  Parameters QIC QIC_u 
Unstructured  cpi baseline, dx, month (cat), dx x month (cat) 9 55736.23 55734.97 
Exchangeable  cpi baseline, dx, month (cat), dx x month (cat) 9 55343.11 55734.97 
Unstructured  cpi baseline, dx, month (cat) 6 56601.26 56597.7 
Exchangeable  cpi baseline, dx, month (cat) 6 56085.82 56081.5 
Unstructured  cpi baseline, dx, month (con) 4 56821.3 56816.14 
Exchangeable  cpi baseline, dx, month (con) 4 56688.48 56682.57 
Unstructured  cpi baseline, dx, month (con), dx x month (con) 5 56725.57 56720.83 
Exchangeable  cpi baseline, dx, month (con), dx x month (con) 5 56587.84 56582.31 
           QIC: Quasilikelihood under the Independence model Criterion, cpi: characteristic pain intensity, dx:  
diagnosis, cat: categorical, con: continuous, dx x month (cat): interaction diagnosis and categorical month, 
dx x month (con): interaction diagnosis and continuous month. 
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Table 4:  Model predicted CPI differences showing best and alternative models.  
	  
Model	  2	  	  (best	  model)	  
	  
Model	  3	  (best	  model	  plus	  
covariates)	  
Model	  4	  (best	  model	  plus	  
covariates	  plus	  imputation)	  
	  
Alternative	  model	  plus	  covariates	  
	  
CPI	  level	  for	  
patients	  w/o	  
migraine	  
Additional	  CPI	  
for	  patients	  w	  
migraine	  
	  
CPI	  level	  for	  
patients	  w/o	  
migraine	  
Additional	  CPI	  
for	  patients	  w	  
migraine	  
	  
CPI	  level	  for	  
patients	  w/o	  
migraine	  
Additional	  CPI	  
for	  patients	  w	  
migraine	  
	  
CPI	  level	  for	  
patients	  w/o	  
migraine	  
Additional	  CPI	  
for	  patients	  w	  
migraine	  
1	  month	   45.9	  
(41.4-­‐50.4)	  
8.9	  
(-­‐3.2-­‐21.0)	  
	  
45.8	  
(41.4-­‐50.2)	  
10.6	  
(-­‐1.6-­‐22.9)	  
	  
47.3	  
(42.0-­‐52.6)	  
8.4	  
(-­‐3.4-­‐20.2)	  
	  
45.1	  
(41.0-­‐49.2)	  
11.6	  
(2.7-­‐20.4)	  
6	  months	   38.2	  
(32.7-­‐43.7)	  
5.7	  
(-­‐10.9-­‐22.3)	  
	  
38.4	  
(33.0-­‐43.8)	  
8.7	  
(-­‐8.0-­‐25.4)	  
	  
39.8	  
(34.5-­‐45.1)	  
7.4	  
(-­‐5.7-­‐20.6)	  
	  
40.4	  
(37.0-­‐43.8)	  
11.6	  
(2.7-­‐20.4)	  
12	  months	   35.1	  
(29.7-­‐40.5)	  
3.1	  
(-­‐9.6-­‐15.7)	  
	  
34.8	  
(29.5-­‐40.1)	  
5.4	  
(-­‐7.3-­‐18.2)	  
	  
35.7	  
(30.7-­‐40.8)	  
5.1	  
(-­‐6.3-­‐16.5)	  
	  
34.6	  
(31.3-­‐37.9)	  
11.6	  
(2.7-­‐20.4)	  
18	  months	   29.2	  
(24.8-­‐33.7)	  
15.0	  
(3.7-­‐26.3)	  
	  
29.2	  
(24.8-­‐33.5)	  
16.5	  
(5.2-­‐27.8)	  
	  
29.6	  
(25.4-­‐33.9)	  
10.3	  
(-­‐1.1-­‐21.7)	  
	  
28.9	  
(24.8-­‐33.0)	  
11.6	  
(2.7-­‐20.4)	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Figure 1: Progression of modeling approach. 
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Figure 2: Graphic representation of the model predicted CPI differences showing best 
and alternative models. 
 
 
Best model (C) shows a combination of main effects, interactions and covariates. 
The alternative model (D) shows only main effects with covariates.  
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